2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Malignant Paraganglioma: new trials by email Literature Review of Malignant Paraganglioma trials Research Report on Malignant Paraganglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma anlotinib hydrochloride - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma | Phase 2 | Completed | Peking Union Medical College Hospital | 27 | 2021-04-30 | 2024-06-12 |
| Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma | Phase 2 | Completed | Mayo Clinic | 3 | 2017-05-31 | 2024-02-20 |
Paraganglioma, Extra-Adrenal (2) · Pheochromocytoma (2) · Neoplasm Metastasis (1) · Paraganglioma (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Neoplastic Processes (1) · Paraganglioma (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
anlotinib (1) · lenvatinib (1)
Mayo Clinic (1) · Peking Union Medical College Hospital (1)
China (1) · United States (1)
Anli Tong (1) · Ashish Chintakuntlawar (1)
P30CA015083 (1)